Vanda Pharmaceuticals (VNDA) Tops Q4 EPS by 8c
Tweet
Share
E-mail
Get Alerts VNDA Hot Sheet
Price: $5.13 +0.39%
EPS Growth %: -60.5%
Financial Fact:
Intangible asset amortization: 2.94M
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: -60.5%
Financial Fact:
Intangible asset amortization: 2.94M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q4 EPS of ($0.01), $0.08 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $38.24 million versus the consensus estimate of $38.39 million.
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Redburn upgrades Southwest, stays bullish on Delta and United
- Forgent Power Solutions, Inc. (FPS) Tops Q2 EPS by 1c, Beats on Revenue; Offers FY27 Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
